AF 05

Drug Profile

AF 05

Alternative Names: AF-05; AF-5

Latest Information Update: 01 Mar 2016

Price : $50

At a glance

  • Originator Institute of Materia Medica
  • Developer Beijing Collab Pharma; Institute of Materia Medica
  • Class Sesquiterpenes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Anxiety disorders

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Anxiety disorders in China (unspecified route)
  • 30 Nov 2009 Phase-I clinical trials in Anxiety disorders in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top